28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial
G Feldman, RR Walker, J Brooks, R Mehta… - Pulmonary …, 2012 - Elsevier
BACKGROUND: Umeclidinium (UMEC; GSK573719) is a new long-acting muscarinic
antagonist (LAMA) currently in development in combination with vilanterol (VI), an inhaled …
antagonist (LAMA) currently in development in combination with vilanterol (VI), an inhaled …
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease
MG Matera, P Rogliani, M Cazzola - Expert opinion on …, 2014 - Taylor & Francis
Introduction: Long-acting muscarinic receptor antagonists (LAMAs) are central to the
treatment of chronic obstructive pulmonary disease (COPD) because of the important role of …
treatment of chronic obstructive pulmonary disease (COPD) because of the important role of …
Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
R Mehta, D Kelleher, A Preece, S Hughes… - International journal of …, 2013 - Taylor & Francis
Background The combination of umeclidinium (UMEC), a long-acting muscarinic receptor
antagonist, and vilanterol (VI), a selective long-acting β2 agonist, is in development for the …
antagonist, and vilanterol (VI), a selective long-acting β2 agonist, is in development for the …
Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?
D Spina - European clinical respiratory journal, 2015 - Taylor & Francis
Bronchodilators are mainstay for the symptomatic treatment of chronic obstructive pulmonary
disease (COPD) and the introduction of long-acting bronchodilators has led to an …
disease (COPD) and the introduction of long-acting bronchodilators has led to an …
Inhaled umeclidinium in COPD patients: a review and meta-analysis
A number of new agents for the management of chronic obstructive pulmonary disease
(COPD) are at different stages of development, including several inhaled long-acting …
(COPD) are at different stages of development, including several inhaled long-acting …
Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies
R Tal-Singer, A Cahn, R Mehta, A Preece… - European journal of …, 2013 - Elsevier
To characterise the safety, tolerability, pharmacodynamics (bronchodilatory effect) and
pharmacokinetics of inhaled umeclidinium in patients with chronic obstructive pulmonary …
pharmacokinetics of inhaled umeclidinium in patients with chronic obstructive pulmonary …
The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease
DP Tashkin - Expert Opinion on Drug Safety, 2015 - Taylor & Francis
Introduction: Poorly absorbable quaternary ammonium-inhaled muscarinic antagonists both
as the short-acting ipratropium and as long-acting (12–24 h) agents (tiotropium …
as the short-acting ipratropium and as long-acting (12–24 h) agents (tiotropium …
Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy
KS Babu, JB Morjaria - Therapeutic Advances in Chronic …, 2017 - journals.sagepub.com
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality
and health care expenditure throughout the world. COPD guidelines recommend the use of …
and health care expenditure throughout the world. COPD guidelines recommend the use of …
Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit?
GP Currie, BJ Lipworth - QJM: An International Journal of …, 2016 - academic.oup.com
Since chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
obstruction, inhaled bronchodilators form the mainstay of treatment. A variety of new inhaled …
obstruction, inhaled bronchodilators form the mainstay of treatment. A variety of new inhaled …